A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804

Summary

There is no difference in the rate and extent of absorption of the material sparing tablet (MST), the Phase2b/3 formulation (P2b/3) with sodium lauryl sulphate (SLS) and the p2b/3 formulation without SLS.

Conditions

• Healthy

Interventions

DRUG

PH-797804 material sparing tablet

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 with sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 with sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 material sparing tablet

oral, 6mg, single dose

DRUG

PH-797804 material sparing tablet

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 without sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 without sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 material sparing tablet

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 without sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 with sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 with sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 without sodium lauryl sulphate

oral, 6mg, single dose

Sponsors & Collaborators

• Pfizer

  lead INDUSTRY

Principal Investigators

• Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

CROSSOVER

Eligibility

Min Age

21 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2010-11-30

Primary Completion

2011-03-31

Completion

2011-03-31

Countries

• Singapore

Study Locations